We are live on
!
Find out more
SCM
Stonepine Capital Management Portfolio holdings
AUM
$250M
1-Year Est. Return
77.6%
This Fund
S&P 500
This Quarter
Est. Return
-5.09%
1 Year Est. Return
+77.6%
3 Year Est. Return
+198.76%
5 Year Est. Return
+226.15%
10 Year Est. Return
+1,976.54%
AUM
$220M
AUM Growth
+$28.5M
(+15%)
Cap. Flow
+$38.3M
Cap. Flow
% of AUM
17.42%
Top 10 Holdings %
Top 10 Hldgs %
81.25%
Holding
35
New
9
Increased
14
Reduced
7
Closed
4
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AMYT
Amryt Pharma plc American Depositary Shares
AMYT
|
+$33.9M |
| 2 |
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
|
+$14.5M |
| 3 |
GMDA
Gamida Cell Ltd. Ordinary Shares
GMDA
|
+$6.4M |
| 4 |
ADMS
Adamas Pharmaceuticals
ADMS
|
+$5.93M |
| 5 |
Ovid Therapeutics
OVID
|
+$4.57M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CHMA
Chiasma, Inc. Common Stock
CHMA
|
+$32M |
| 2 |
CFMS
Conformis, Inc. Common Stock
CFMS
|
+$8.66M |
| 3 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
+$3.27M |
| 4 |
XOMA
Xoma
XOMA
|
+$2.84M |
| 5 |
EyePoint Inc
EYPT
|
+$2.13M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 90.44% |
| 2 | Financials | 0.46% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CFMS
26
DELISTED
Conformis, Inc. Common Stock
CFMS
| $648K | 0.29% |
19,479
-245,564
| -93% | -$8.66M |
|
|
NBSE
27
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
| $396K | 0.18% |
5,487
+3,933
| +253% | +$301K |
|
28
Immunic
IMUX
$191M
| $198K | 0.09% |
+2,241
| New | +$221K |
|
|
CFRX
29
DELISTED
ContraFect Corporation
CFRX
| $139K | 0.06% |
430
-410
| -49% | -$128K |
|
|
SPNE
30
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
| $131K | 0.06% |
+8,349
| New | +$143K |
|
31
SCYNEXIS
SCYX
$37M
| $34K | 0.02% |
791
+778
| +5,985% | +$40.7K |
|
32
Corvus Pharmaceuticals
CRVS
$1.11B
| – | – |
-46,886
| Closed | -$125K |
|
|
ISEE
33
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| – | – |
-517,445
| Closed | -$3.27M |
|
|
AGTC
34
DELISTED
Applied Genetic Technologies Corporation
AGTC
| – | – |
-1,000
| Closed | -$4K |
|
|
CHMA
35
DELISTED
Chiasma, Inc. Common Stock
CHMA
| – | – |
-6,770,000
| Closed | -$32M |
|
Similar funds
ER
FDDB
VM
PF
SCM
CWM
EWM
RA
Stonepine Capital Management's Q3 2021 Portfolio in Review
As of Q3 2021, Stonepine Capital Management held 35 positions worth $220M, up 15% from $191M the previous quarter. Its ten largest holdings account for 81% of the portfolio.
Stonepine Capital Management deployed $38.3M of net new capital in Q3 2021, opening 9 new positions and adding to 14 existing holdings. Its largest new stake was Lakefront Biotherapeutics American Depositary Shares: 244,205 shares worth $12.8M.
By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 89% a quarter earlier, followed by Financials.
On the sell side, the largest reduction was Conformis, Inc. Common Stock, an estimated $8.66M trimmed.
- Stonepine Capital Management's largest Q3 2021 buy was Lakefront Biotherapeutics American Depositary Shares: 244,205 shares worth $12.8M.
- Stonepine Capital Management added most to Amryt Pharma plc American Depositary Shares in Q3 2021, an estimated $33.9M increase.
- Stonepine Capital Management's biggest Q3 2021 reduction was Conformis, Inc. Common Stock, cutting an estimated $8.66M.
- Stonepine Capital Management fully exited Chiasma, Inc. Common Stock in Q3 2021, selling an estimated $32M.
- Stonepine Capital Management's ten largest holdings make up 81% of its $220M portfolio in Q3 2021.
- Stonepine Capital Management opened 9 new positions and closed 4 in Q3 2021.
- Stonepine Capital Management's portfolio value rose 15% quarter-over-quarter to $220M.
Based on Stonepine Capital Management's 13F filing for Q3 2021, filed 12 Nov 2021.